• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

哥伦比亚波哥大低收入地区5岁以下儿童接种肺炎球菌疫苗和流感疫苗的成本效益分析

Cost-Effectiveness Analysis of Pneumococcal and Influenza Vaccines Administered to Children Less Than 5 Years of Age in a Low-Income District of Bogota, Colombia.

作者信息

Lara Carlos, De Graeve Diana, Franco Fabian

机构信息

Department of Economics, University of Antwerp, Antwerp, Belgium.

Department of Economics, University of Antwerp, Antwerp, Belgium.

出版信息

Value Health Reg Issues. 2018 Dec;17:21-31. doi: 10.1016/j.vhri.2018.01.001. Epub 2018 Apr 5.

DOI:10.1016/j.vhri.2018.01.001
PMID:29626706
Abstract

BACKGROUND

The Colombian health authorities introduced the pneumococcal conjugated vaccine and the seasonal influenza vaccine into the national immunization schedule for children in 2009 and 2007, respectively. Despite this, the health authorities continue to be concerned about the high economic and disease burden among children from low-income households caused by these vaccine-preventable diseases.

OBJECTIVES

  1. To evaluate the potential health outcomes of four vaccination strategies for subsidized children younger than 5 years in a low-income district in Colombia from a public, direct medical health care perspective. 2) To perform univariate, multivariate, and probabilistic sensitivity analysis to evaluate the robustness of these results.

METHODS

We built a Markov deterministic cohort model to evaluate five consecutive cohorts across four alternative situations: 1) no vaccination; 2) vaccination with the 10-valent pneumococcal conjugate vaccine (PCV10 vaccine); 3) vaccination with the trivalent inactivated vaccine (TIV) annually; and 4) combined vaccination with PCV10 vaccine and TIV.

RESULTS

The introduction of PCV10 vaccine and TIV and their combined use in particular would be highly cost-effective in comparison to no vaccination. For the combined vaccination with PCV10 vaccine and TIV, the incremental cost-effectiveness ratio would be $1,280 per disability-adjusted life-year (DALY) averted, the total incremental cost of the vaccination program would be $776,800, and it would avert four deaths and 332 DALYs for the five cohorts.

CONCLUSIONS

The introduction of PCV10 vaccine and TIV would be highly cost-effective from a public, direct medical health care perspective. Despite these results, we have not observed decreases in severity or hospitalizations. Our findings highlight the need for further studies of the immunization campaign indicators and socioeconomic indicators for this low-income community.

摘要

背景

哥伦比亚卫生当局分别于2009年和2007年将肺炎球菌结合疫苗和季节性流感疫苗纳入国家儿童免疫规划。尽管如此,卫生当局仍对这些疫苗可预防疾病给低收入家庭儿童带来的高经济和疾病负担感到担忧。

目的

1)从公共直接医疗保健角度评估哥伦比亚一个低收入地区5岁以下补贴儿童的四种疫苗接种策略的潜在健康结果。2)进行单变量、多变量和概率敏感性分析,以评估这些结果的稳健性。

方法

我们构建了一个马尔可夫确定性队列模型,以评估四种替代情况下的五个连续队列:1)不接种疫苗;2)接种10价肺炎球菌结合疫苗(PCV10疫苗);3)每年接种三价灭活疫苗(TIV);4)联合接种PCV10疫苗和TIV。

结果

与不接种疫苗相比,引入PCV10疫苗和TIV,尤其是联合使用,具有很高的成本效益。对于联合接种PCV10疫苗和TIV,每避免一个伤残调整生命年(DALY)的增量成本效益比为1280美元,疫苗接种计划的总增量成本为776,800美元,并且对于五个队列可避免4例死亡和332个DALY。

结论

从公共直接医疗保健角度来看,引入PCV10疫苗和TIV具有很高的成本效益。尽管有这些结果,但我们并未观察到严重程度或住院率的下降。我们的研究结果强调了对这个低收入社区的免疫活动指标和社会经济指标进行进一步研究的必要性。

相似文献

1
Cost-Effectiveness Analysis of Pneumococcal and Influenza Vaccines Administered to Children Less Than 5 Years of Age in a Low-Income District of Bogota, Colombia.哥伦比亚波哥大低收入地区5岁以下儿童接种肺炎球菌疫苗和流感疫苗的成本效益分析
Value Health Reg Issues. 2018 Dec;17:21-31. doi: 10.1016/j.vhri.2018.01.001. Epub 2018 Apr 5.
2
Cost-effectiveness of pneumococcal conjugate vaccination in Croatia.克罗地亚肺炎球菌结合疫苗接种的成本效益
Vaccine. 2015 May 7;33 Suppl 1:A209-18. doi: 10.1016/j.vaccine.2014.12.043.
3
Cost-effectiveness of pneumococcal conjugate vaccination in Georgia.格鲁吉亚肺炎球菌结合疫苗接种的成本效益
Vaccine. 2015 May 7;33 Suppl 1:A219-26. doi: 10.1016/j.vaccine.2014.12.070.
4
How cost effective is switching universal vaccination from PCV10 to PCV13? A case study from a developing country.将通用疫苗接种从 PCV10 切换到 PCV13 的成本效益如何?来自发展中国家的案例研究。
Vaccine. 2018 Sep 11;36(38):5766-5773. doi: 10.1016/j.vaccine.2018.07.078. Epub 2018 Aug 4.
5
Economic evaluation of pneumococcal conjugate vaccination in The Gambia.冈比亚肺炎球菌结合疫苗的经济学评价。
BMC Infect Dis. 2010 Sep 3;10:260. doi: 10.1186/1471-2334-10-260.
6
Cost-effectiveness analysis of 10- and 13-valent pneumococcal conjugate vaccines in Peru.秘鲁10价和13价肺炎球菌结合疫苗的成本效益分析。
Vaccine. 2015 May 7;33 Suppl 1:A154-66. doi: 10.1016/j.vaccine.2014.12.039.
7
Cost-effectiveness of a 10- versus 13-valent pneumococcal conjugate vaccine in Denmark and Sweden.丹麦和瑞典 10 价与 13 价肺炎球菌结合疫苗的成本效益分析。
Clin Ther. 2013 Feb;35(2):119-34. doi: 10.1016/j.clinthera.2012.12.006. Epub 2013 Jan 10.
8
Cost-effectiveness analysis of the introduction of the pneumococcal conjugate vaccine (PCV-13) in the Egyptian national immunization program, 2013.2013年埃及国家免疫规划中引入肺炎球菌结合疫苗(PCV-13)的成本效益分析
Vaccine. 2015 May 7;33 Suppl 1:A182-91. doi: 10.1016/j.vaccine.2014.12.044.
9
Postintroduction Study of Cost-Effectiveness of Pneumococcal Vaccine PCV10 from Public Sector Payer's Perspective in the State of Santa Catarina, Brazil.从巴西圣卡塔琳娜州公共部门支付方角度对肺炎球菌疫苗PCV10成本效益的引入后研究
Value Health Reg Issues. 2018 Dec;17:109-114. doi: 10.1016/j.vhri.2017.12.008. Epub 2018 May 15.
10
Cost-effectiveness analysis of pneumococcal conjugate vaccine introduction in Paraguay.巴拉圭引入肺炎球菌结合疫苗的成本效益分析。
Vaccine. 2015 May 7;33 Suppl 1:A143-53. doi: 10.1016/j.vaccine.2014.12.078.

引用本文的文献

1
Economic Burden of Respiratory Viruses in Latin America and the Caribbean (LAC): A Scoping Literature Review.拉丁美洲和加勒比地区呼吸道病毒的经济负担:一项范围界定文献综述
Influenza Other Respir Viruses. 2025 Sep;19(9):e70148. doi: 10.1111/irv.70148.
2
Costs and cost-effectiveness of influenza illness and vaccination in low- and middle-income countries: A systematic review from 2012 to 2022.中低收入国家流感疾病和疫苗接种的成本及成本效益:2012 年至 2022 年的系统评价。
PLoS Med. 2024 Jan 5;21(1):e1004333. doi: 10.1371/journal.pmed.1004333. eCollection 2024 Jan.
3
Inclusion of Additional Unintended Consequences in Economic Evaluation: A Systematic Review of Immunization and Tuberculosis Cost-Effectiveness Analyses.
经济评估中纳入其他意外后果:免疫接种和结核病成本效益分析的系统评价
Pharmacoecon Open. 2021 Dec;5(4):587-603. doi: 10.1007/s41669-021-00269-4. Epub 2021 May 4.
4
Estimating the Impact of Switching from a Lower to Higher Valent Pneumococcal Conjugate Vaccine in Colombia, Finland, and The Netherlands: A Cost-Effectiveness Analysis.评估在哥伦比亚、芬兰和荷兰从低价次向高价次肺炎球菌结合疫苗转换的影响:一项成本效益分析。
Infect Dis Ther. 2020 Jun;9(2):305-324. doi: 10.1007/s40121-020-00287-5. Epub 2020 Feb 24.